Featured news from NHIVNA
HIV-related news from NAM
Tenofovir, boosted atazanavir and boosted lopinavir are associated with cumulative risk of developing chronic kidney disease
Gus Cairns, 2015-02-27 15:00:00
Three antiretroviral drugs are associated with a slowly increasing rate of chronic kidney disease over time, the Conference on Retroviruses and Opportunistic Infections (CROI 2015) in Seattle, USA, heard today.
Although the risk of developing chronic kidney disease (CKD) was low for people with normal kidney function, with fewer than 1% of patients in the large cohort studied developing it, the use of any one of these three drugs was associated with two to three times the risk of chronic kidney disease developing over the course of five years on the drug, delegates heard.
In the case of tenofovir, the rate of chronic kidney disease remained two to three times over normal levels after the drug was stopped, at least up to two years after it was withdrawn.
In contrast, while people taking abacavir or boosted protease inhibitors (PIs) also experienced a rise in the rate of chronic kidney disease, the risk did not accumulate over time, and appeared to be related to patient factors, rather than the drug.
Source:1
